Denali Therapeutics Inc.

NasdaqGS:DNLI 株式レポート

時価総額：US$3.0b

Denali Therapeutics 過去の業績

過去 基準チェック /06

Denali Therapeuticsの収益は年間平均-32%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 41.9%割合で 減少しています。

主要情報

-31.98%

収益成長率

-24.21%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率-41.86%
株主資本利益率-54.86%
ネット・マージンn/a
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

Seeking Alpha • May 03

Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform

Summary Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI’s TransportVehicle technology enables delivery of biologics across the blood-brain barrier, providing significant differentiation and commercial potential in neurodegenerative and lysosomal storage diseases. With $1.17 billion in pro-forma liquidity and a focused initial launch, DNLI is positioned for 2.8 years of runway, reducing near-term capital risk. While valuation appears high on sales multiples, DNLI’s now-validated platform and pipeline optionality make the current price/book premium reasonable for early-stage commercial growth. Read the full article on Seeking Alpha
分析記事 • May 08

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 20

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson’s Disease asset DNL151 includes substantial milestone payments and profit-sharing, highlighting its potential impact. Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Read the full article on Seeking Alpha
Seeking Alpha • Jan 09

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Summary Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ALS, Denali's stock remains stable due to continued pre-specified analyses expected in late 2025. BLA filing of tividenofusp alfa for the treatment of patients with MPS II remains on track under the Accelerated Approval Pathway Program in early 2025. Financially, Denali has $1.28 billion in cash but may need additional funding in 2025, posing a risk of shareholder dilution. Read the full article on Seeking Alpha
分析記事 • Dec 09

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 20

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Summary Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company’s $500 million capital raise supports its aggressive R&D investment, providing a runway for developing its pipeline. Despite its promising platform, DNLI still has a relatively high cash burn and regulatory hurdles before achieving drug approval. Due to Denali's high-risk, long-term biotech development, I deem DNLI a DCA "buy" for investors who understand the inherent risks. Read the full article on Seeking Alpha
分析記事 • Jul 26

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • May 23

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics Inc. ( NASDAQ:DNLI ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • May 13

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Summary Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of patients with MPS II. Biomarker and safety data from a phase 1/2 study, using DNL-126 for the treatment of patients with MPS IIIA, expected end of 2024. Another promising program from the pipeline is the development of DNL-343, which is being advanced in the phase 2/3 HEALEY ALS Platform trial for treatment of patients with amyotrophic lateral sclerosis. Read the full article on Seeking Alpha
分析記事 • Apr 17

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.71 Denali...
分析記事 • Mar 21

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Those holding Denali Therapeutics Inc. ( NASDAQ:DNLI ) shares would be relieved that the share price has rebounded 25...
Seeking Alpha • Mar 07

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. Denali boasts a strong financial position with $1.53 billion in cash, extending operational runway significantly. Recommends "buy" based on Denali's innovative TV technology, financial health, and potential in neurological disorders despite biotech risks. Read the full article on Seeking Alpha
分析記事 • Feb 21

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Jan 26

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Denali Therapeutics Inc.'s ( NASDAQ:DNLI ) price-to-sales (or "P/S") ratio of 7x might make it look like a buy right...
分析記事 • Nov 20

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • Oct 09

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

With a median price-to-sales (or "P/S") ratio of close to 10.4x in the Biotechs industry in the United States, you...
分析記事 • Aug 22

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

収支内訳

Denali Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:DNLI 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 260-5081410
31 Dec 250-5131370
30 Sep 250-4991270
30 Jun 250-4791170
31 Mar 250-4541100
31 Dec 240-4231050
30 Sep 240-4271000
30 Jun 241-420101-194
31 Mar 24295-1371010
31 Dec 23331-1451030
30 Sep 23341-1241020
30 Jun 23343-128100194
31 Mar 23101-371950
31 Dec 22108-326900
30 Sep 22111-303890
30 Jun 22112-284850
31 Mar 2283-286830
31 Dec 2149-291790
30 Sep 2135330750
30 Jun 2135756720
31 Mar 2134058670
31 Dec 2033671600
30 Sep 2024-228530
30 Jun 2028-216490
31 Mar 2026-215500
31 Dec 1927-198460
30 Sep 19148-66470
30 Jun 19135-55440
31 Mar 19133-52360
31 Dec 18129-36320
30 Sep 183-137260
30 Jun 182-123210
31 Mar 181-91180
31 Dec 170-88160
30 Sep 170-851417
30 Jun 170-931339
31 Mar 170-901255
31 Dec 160-87120

質の高い収益: DNLIは現在利益が出ていません。

利益率の向上: DNLIは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: DNLIは利益が出ておらず、過去 5 年間で損失は年間32%の割合で増加しています。

成長の加速: DNLIの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: DNLIは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。

株主資本利益率

高いROE: DNLIは現在利益が出ていないため、自己資本利益率 ( -54.86% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/24 04:44
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Denali Therapeutics Inc. 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31

アナリスト機関
null nullBaird
Joel BeattyBaird
Charles MooreBaird